Pharma Focus Asia

Daiichi Sankyo Invests US$1.12 billion (€1 billion) to Expand Innovation Centre in Munich, Germany

Introduction:

Daiichi Sankyo with an investment of US$1.12 billion (€1 billion) plans to expand production and development site in Pfaffenhofen an daer Ilm in Germany.

Features:

The Pfaffenhofen facility is recognised globally as a leading site for producing clinical products. New analysis methods, crucial for maintaining quality standards, are carefully developed within the analytical department.

These methods are crafted within the analytical department and later employed in quality control processes to thoroughly assess the final medicinal products.

The opening of a new building in late 2023 offered sufficient space to accommodate both departments, reflecting a committed endeavour to enhance efficiency and accuracy in production.

In addition to boosting production for cardiovascular diseases, new labs are specifically designed for antibody drug conjugate technology (ADC). These labs will focus on developing and producing innovative cancer therapies for breast, lung, and stomach cancers.

The expansion also involves hiring top-notch international researchers, process engineers, and other experts in sterile and biotechnology fields.

This expansion project has already commenced and is slated for completion no later than 2030.

Specifications:

Name       Daiichi Sankyo
Type         New Construction
Budget    US$1.12 billion (€1 billion)
Year          2030

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference